Concentration-effect curves for oxaliplatin in the colorectal cancer line HCT116. An average IC 50 value of 35 ± 6 µM ensured that a concentration of 5 µM oxaliplatin was adequate (sub-cytotoxic) for the following preparations.
Figure S4
Chromatogram of a 10 µM multicomponent standard measured on the UPLC BEH Amide column at pH 4 in positive mode.
Figure S5
Chromatogram of a 10 µM multicomponent standard measured on the UPLC BEH Amide column at pH 4 in negative mode. 0  0  100  0  0  100  2  0  100  2  0  100  2  0  100  8  100  0  13  100  0  8  50  50  10  100  0  15  100  0  10  50  50  10  0  100  15  0  100  10  0  100  15  0  100  20  0  100  15  0  100 *50 mM CH 3 COONH 4 for pH6.
**40°C for the column Acquity UPLC BEH Amide.
***The mixed mode columns Trinity P1 and Trinity P2 required 1 h pre-equilibration prior to the analysis. *Isomers which could be separated on the UPLC BEH Amide column at pH 4 in positive mode. For further identification an analysis of the single standard is necessary. *corresponding mainly to nucleotides. Their peak width increased with the number of phosphates.
Figure S6
Heatmap of the different compounds found in sensitive and resistant HCT116 cell control for 24 h. Method: UPLC BEH Amide at pH 4 in positive and negative mode combining targeted (internal standardization) and untargeted metabolomics. Hierarchical clustering separated the two investigated groups. Sensitive HCT116 cells showed overall higher metabolite amounts as compared to the resistant counterpart, with the exception of N1,N12diacetylspermine, cystathionine, uridine 5´-diphosphoglucuronic acid and 5´-deoxy-5´methylthioadenosine. 
Figure S9
Heatmap of the different compounds found in sensitive HCT116 cell control and in sensitive HCT116 cell incubated with oxaliplatin 5 µM for 24 h. Method: UPLC BEH Amide at pH 4 in positive and negative mode combining targeted (internal standardization) and untargeted metabolomics. A clear separation could be observed between sensitive cells with and without drug (denoted as sensitive control). Overall the metabolite levels were higher in the sensitive line control experiment, with the exception of 3-phosphoglycerate, 6phosphogluconate, uridine 5´-diphosphoglucuronic acid palmitoylcarnitine, N8acetylspermine and N1,N12-diacetylspermine.
Figure S10
Principal component analysis of sensitive HCT116 cell control vs sensitive HCT116 incubated with oxaliplatin 5 µM for 24 h. Method: UPLC BEH Amide at pH 4 in positive and negative mode combining targeted (internal standardization) and untargeted metabolomics. A clear separation could be observed between both groups.
Figure S11
Heatmap of the different compounds found in resistant HCT116 cell control and in resistant HCT116 cell incubated with oxaliplatin 5 µM for 24 h. Method: UPLC BEH Amide at pH 4 in positive and negative mode combining targeted (internal standardization) and untargeted metabolomics. Only subtle changes could be observed.
Figure S12
Principal component analysis of resistant HCT116 cell control vs resistant HCT116 incubated with oxaliplatin 5 µM for 24 h. Method: UPLC BEH Amide at pH 4 in positive and negative mode combining targeted (internal standardization) and untargeted metabolomics. The separation between both groups was not pronounced.
Table S10
Pearson correlation of the different metabolites (and their associated pathways) with the incubation time (4, 8, 24 h) in targeted metabolomics. Samples: sensitive HCT116 cell control and sensitive HCT116 cell incubated with 5 µM oxaliplatin. Method: UPLC BEH Amide at pH 4 in positive and negative mode with internal standardization and protein normalization. Differences in Pearson correlation between experiments without (sensitive control) and with drug incubation (sensitive oxaliplatin) were interpreted as metabolic perturbation exerted by the drug. The highest differences in the Pearson correlation are found for dihydroxyacetonephosphate, 2/3-Phosphoglycerate, glutamine, fructose-1,6bisphosphate, serine, adenine, GMP and pyruvate. 
